Sabaa International Company for Pharmaceutial and Chemical Industry
EEGX:SIPC5.04
EGP
-0.35
(-6.49%)
ISIN
EGS382M1C011
Return %
Stock
S&P 500
1Y
70.27
14.20
3Y
608.86
81.12
5Y
365.80
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Mohammed Abdul Nabi Mohamed El Beily
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Cairo Egypt
- IPO Date
- Oct 10, 2013
- Website
- sabaapharmagroup.com
- Similar Companies
- Business
- Sabaa International Company for Pharmaceutical and Chemical Industry SAE is an Egypt-based healthcare manufacturing and commercial enterprise engaged in the research, development, production, and distribution of generic pharmaceuticals, veterinary medicines, nutritional food supplements, cosmetics, and active chemical products. Founded in May 2000 and headquartered in Cairo, Egypt, the company operates a primary manufacturing facility located in the Baltim industrial zone within the Kafr El Sheikh Governorate, serving domestic hospitals, retail pharmacies, and regional export markets across the Middle East and North Africa. Sabaa International operates across multiple healthcare sectors and maintains a specialized product portfolio comprising hard gelatin capsules, such as Acitretin for dermatological conditions; film-coated and compressed oral solid tablets, such as Saboctic for diabetic neuropathy, Topiramate for neurological treatments, Tolterodine for urological disorders, Claudol for peripheral vascular therapy, and Flamogen E.C.T. for anti-inflammatory care; broad-spectrum generic prescription pharmaceuticals covering central nervous system, cardiovascular, and metabolic therapeutic categories; over-the-counter healthcare formulations and dietary supplements; veterinary therapeutic preparations; and contract manufacturing services, including toll manufacturing, formulation testing, medicine trial support, quality assurance verification, and packaging solutions for third-party pharmaceutical enterprises. In recent developments, Sabaa International has advanced several operational and strategic initiatives, including capital structure adjustments approved through shareholder bonus share issuances to enhance working capital, ongoing expansion and line optimization at its Baltim manufacturing plant, the registration and market introduction of new generic therapeutic formulations, the upgrading of its quality control laboratories in accordance with Egyptian Drug Authority standards, and the scaling of third-party toll manufacturing agreements to support increased domestic supply requirements and regional trade opportunities.